Aelis Farma first established its research and development on an exclusive collaboration with the Neurocentre Magendie in Bordeaux, one of the most respected and highly innovative Neuroscience Research centers in Europe with extensive experience in the CB1 receptor.
Recently, Aelis Farma extended its portfolio of international collaborations :
These extremely prestigious laboratories are complementary to Magendie for developing new signaling biased drugs. Thanks to this strategy, Aelis Farma has secured the most knowledge and expertise in the field of signaling specific drugs for the CB1 receptor and other similar GPCRs.
In collaboration with Columbia University, Aelis Farma has been granted a 3.3 MUSD financing from NIDA (National Institute on Drug Abuse) in order to finance the first clinical studies for its lead compound AEF0117 in the treatment of cannabis abuse. To comply with specific NIH requirements, Aelis Farma has set up a FCOI (Financial Conflicts of Interest) policy which can be provided upon request at the following address: email@example.com.